Sonoma Pharmaceuticals : Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
January 23, 2020 at 02:34 am IST
Share
UNITED STATES
OMB APPROVAL
OMB Number:
3235-0080
Expires:
March 31, 2018
Estimated average burden
hours per response:
1.7
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 25
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number
001-33216
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
Address:
1129 North McDowell Blvd
Petaluma
CALIFORNIA
94954
Telephone number:
1 707 283-0550
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
Warrant expiring 1/26/2020
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
Pursuant to the requirements fo the Securities Exchange Act of 1934, The Nasdaq Stock Market LLCcertifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
2020-01-22
By
Tara Petta
Director
Date
Name
Title
1
Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Attachments
Original document
Permalink
Disclaimer
Sonoma Pharmaceuticals Inc. published this content on 22 January 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 January 2020 21:03:01 UTC
Sonoma Pharmaceuticals, Inc. is a global healthcare company, which is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, eye care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. The Company's product offerings include Lumacyn Clarifying Mist; Regenacyn Advanced Scar Gel; Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel; Microcyn OTC Advanced Wound & Skin Cleanser; Podiacyn Advanced Everyday Foot Care, MicrocynAH and others. Lumacyn Clarifying Mist is intended for use as a daily skin toner, to soothe and cleanse the skin, reduce redness, and manage blemishes by reducing infection. Podiacyn is intended for management of foot odors, infections, and irritations, as well as daily foot health and hygiene. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a range of animal wounds and infections.
Sonoma Pharmaceuticals : Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities